The Science Behind SelexION Differential Mobility Spectrometry Technology by SCIEX Community | 0 CommentsScientists and analysts across all fields of testing and research are increasingly challenged by complex samples requiring advanced analytical selectivity. And where LC-MS/MS sensitivity alone is not enough to meet the demands of modern day quantitative performance, Differential Ion Mobility Spectrometry (DMS) has proven to be a valuable addition.
Elimination of Interference using the SelexION Differential Mobility System for the Quantitation of Rituximab in a Dual Surrogate Peptide Approach by SCIEX Community | 0 CommentsThe quantitation of proteins using the surrogate peptide approach can complicate nominal mass Triple Quadrupole MRM measurements due to co-extracted interference when using non-selective extraction techniques such as pellet digestion. High resolution coupled with accurate mass filtering can mitigate such interference, as reported previously for the determination of rituximab using the TripleTOF 6600 (Protein Quant Approaches). However, an additional level of selectivity can often be achieved on nominal mass systems using the orthogonal gas-phase separation approach offered by the SelexION+® Differential Mobility System technology (DMS). Interfaced between the sampling orifice and ion source, the DMS separates ions based upon differences in their migration rates under alternating low and high field waveform amplitudes (Figure 1). Ion clustering in low fields and declustering in high fields amplifies the distinction in mobility of an ion, resulting in improved resolution from interfering species of differing molecular cross-section.1-4
Happy Birthday to SWATH Acquisition! 5 Years of Innovation by Christie Hunter | 0 CommentsWith its introduction at the HUPO World Congress in 2010 in Sydney Australia by Ruedi Aebersold, SWATH® Acquisition instantly intrigued scientists around the world. Here was a new technique with the potential to revolutionize the way proteomics studies were performed! Based on a data independent acquisition strategy using a SCIEX TripleTOF® 5600 system, SWATH was able to consistently identify and quantify at least as many peptides and proteins as other far more mature proteomics strategies on the market, but with quantitative accuracy and reproducibility rivaling gold standard MRM experiments! This solution was made broadly available to researchers with a full launch of SWATH Acquisition in the Analyst® TF 1.6 Software on the TripleTOF 5600+ System at ASMS 2012 in Vancouver (A Mine of Quantitative Proteomic Information. Prof Dr. Ruedi Aebersold, Head of the Department of Biology, ETH Zurich).
5 Tips for Calibrating a QTOF Mass Spectrometer by SCIEX Community | 0 CommentsDo you have questions about your mass spec? How about a workflow? Our community members are involved in active discussions and receive expert answers from customers like you, SCIEX scientists, and support specialists every week. One recent topic concerned the automatic calibration on TripleTOF® systems as answered by Dr. Christie Hunter whose focus is developing and testing innovative MS workflows for omics research through working collaboratively with the instrument, chemistry, and software research groups.
Your success and voice go a long way! by Andrea Mueller | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, TechnologyAt the heart of everything we do is ensuring that your workflows and team are empowered to achieve optimal results with your SCIEX instruments, software, consumables, and services. Every interaction with SCIEX is designed to support your success through the dedication...
Pharma perspectives: The influence of LC-MS innovation on drug development outsourcing by Kean Woodmansey | Blogs, Pharma, ZenoTOF 7600 systemIt is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Working for a contract research organization and more recently for SCIEX has provided an interesting perspective on trends the market experiences that affect many of us.
Overcoming uncertainty in your PFAS analysis by Karl Oetjen | Blogs, Environmental / IndustrialJust like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.
6 Signs it’s time for a new vendor by Michael Wonski | Blogs, Instrument maintenance, Optimizing Performance, TechnologyA lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.
Selecting an LC-MS system for quantitation of pharmaceutical drug development by Kirsten Craven | Blogs, Echo® MS+ system, Pharma, QTRAP / Triple Quad, ZenoTOF 7600 systemWe understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
Nitrosamines: Where are we now? by SCIEX Community | Blogs, Pharma, QTRAP / Triple QuadNitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.
PFAS analysis in food: a robustness study in sensitivity and stability by Holly Lee | Blogs, Environmental / Industrial, Food / Beverage, QTRAP / Triple QuadThe combination of per- and polyfluoroalkyl substances (PFAS) testing, trace-level regulatory requirements and complex MS applications can be intimidating. In a recent webinar, now available on demand, SCIEX PFAS expert Craig Butt demonstrated how the new SCIEX 7500+ system can help make PFAS testing easier.
FDA’s final rule on LDTs: what does it mean for clinical laboratories? by Pierre Negri | Blogs, ClinicalOn April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.
LC-MS system replacement: Are you ready? by Kirsten Craven | Blogs, Pharma, QTRAP / Triple QuadMeeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?
An overview: LC-MS analysis of targeted protein degraders and their metabolites by Kirsten Craven | Blogs, Pharma, ZenoTOF 7600 systemTargeted protein degraders (TPD) are a relatively new therapeutic modality that opens the potential to target disease-causing proteins. These disease-causing proteins have been highly challenging for traditional small-molecule therapeutics to treat, making TPDs an exciting new therapeutic modality.